Jakab F, Záborszky A, Sugár I
3rd Department of Medicine, Semmelweis University Medical School, Budapest, Hungary.
Acta Chir Hung. 1987;28(4):345-54.
Preparation of portacaval anastomosis (PCA) in patients suffering from portal hypertension has been an accepted procedure for reducing portal pressure. Recently, fashioning of mesocaval anastomosis has got preference. In the era of portacaval anastomoses numerous experimental works were concerned with the technique of performing them. During these experiments it was revealed that PCA produces considerable changes both in the metabolism and the circulation of the liver. Fischer et al. state that, following PCA, the weight of the liver decreased, on an average by 55%, as compared to the controls. Ossenberg et al. observed that after PCA liver perfusion was reduced by about 55-65%. Rubin et al. demonstrated that the hepatic cytochrome P 450 content was significantly decreased and the function of the microsomal drug metabolizing enzymes markedly altered subsequent to PCA. All these data indicated that, as a results of the bypassing of portal inflow from the liver, PCA significantly influences liver function and the intervention in experimental animals, i.e. rats, can be used as a model for chronic hepatic insufficiency.
对于门静脉高压患者,构建门腔静脉吻合术(PCA)一直是一种被认可的降低门静脉压力的手术方法。近来,肠系膜上腔静脉吻合术更受青睐。在门腔静脉吻合术的时代,众多实验研究都围绕其实施技术展开。在这些实验过程中发现,PCA会使肝脏的代谢和循环产生显著变化。费舍尔等人指出,与对照组相比,实施PCA后,肝脏重量平均下降了55%。奥森伯格等人观察到,PCA后肝脏灌注减少了约55% - 65%。鲁宾等人证明,PCA后肝细胞色素P 450含量显著降低,微粒体药物代谢酶的功能也发生了明显改变。所有这些数据表明,由于门静脉血流绕过肝脏,PCA对肝脏功能有显著影响,对实验动物(即大鼠)的干预可作为慢性肝功能不全的模型。